// App-Quantinova.ai

2316 : Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study

Researchers

Presenter

  • Philippe Moreau

Principal Investigators

  • Meletios A. Dimopoulos

  • Joseph Mikhael

  • Kwee Yong

  • Marcelo Capra

  • Thierry Facon

  • Roman Hajek

  • Ivan Spicka

  • Marie-Laure Risse

  • Gaelle Asset

  • Sandrine Mac

  • Thomas G. Martin III

Medical Centers

  • Department of Hematology, CHU Nantes, Nantes, France

  • National and Kapodistrian University of Athens, Athens, Greece

  • Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ

  • Kings College London, London, United Kingdom

  • Departamento de Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil

  • Department of Hematology, Grenoble University Hospital, Grenoble, France

  • Department of Neurosurgery, University Hospital Ostrava, Ostrava, Czech Republic

  • First Faculty of Medicine, Charles University, Prague, Czech Republic

  • Aixial (for Sanofi), Boulogne-Billancourt, France

  • Sanofi, Chilly-Mazarin, France

  • Sanofi Research and Development, Vitry-Sur-Seine, France

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Locations

  • France

  • Greece

  • United States

  • United Kingdom

  • Brazil

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved